Status:

TERMINATED

Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

Lead Sponsor:

Emory University

Conditions:

High Risk Solid Tumors

Recurrent Solid Tumors

Eligibility:

All Genders

Up to 35 years

Phase:

NA

Brief Summary

Before the transplant, the patient will have a pre-transplant evaluation. This will help find out whether there are health problems that will prevent the transplant. It also provides "baseline" tests ...

Detailed Description

The optimal treatment for refractory (disease won't go away with standard treatment) or relapsed (disease comes back after going away) solid tumors is unknown. Recent studies have shown some benefit t...

Eligibility Criteria

Inclusion

  • Patients diagnosed with high risk recurrent or refractory solid tumors following initial chemotherapy
  • Tumor must be sensitive to chemotherapy (maximum 8 cycles) and/or radiation defined as a greater than 50% reduction in size of the primary and/or metastatic sites.
  • Patients who are under 35 years of age.
  • Patients with a life expectancy of at least 8 weeks and performance status (Karnofsky or Lansky score) of at least 70%.
  • Patients who are acceptable candidates for peripheral blood stem cell transplantation based on their pre-transplant evaluation.

Exclusion

  • Patients will not be excluded based on sex, race.
  • Patients with central nervous system tumors are not eligible for this protocol.
  • Patients have significant functional deficits in major organs which would interfere with successful outcome following PBSCT.
  • Patients who have been treated for infections must have appropriate responses as documented by negative cultures and/or a normal radiographic examination.
  • Patients may not have active CNS disease or marrow involvement with the tumor at the time of transplant.
  • Patients with disease progression after tandem PBSC #1 will not be eligible for tandem PBSC #2.
  • Patients will be excluded if they are women of childbearing potential who are currently pregnant (HCG+) or who are not practicing adequate contraception.
  • Patients who have had a previous stem cell transplant.

Key Trial Info

Start Date :

May 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT00966498

Start Date

May 1 2003

End Date

July 1 2011

Last Update

December 11 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30322

2

Emory University

Atlanta, Georgia, United States, 30322